Long-term treatment of C1 inhibitor deficiency with epsilon-aminocaproic acid in two patients.
Most patients who have hereditary angioedema receive treatment with androgens or impeded androgens. epsilon-Aminocaproic acid (EACA) is another treatment for C1 inhibitor deficiency. In two patients with angioedema and attacks of abdominal pain due to C1 inhibitor deficiency, long-term treatment with EACA (for more than 2 decades in one of them) was associated with a substantial decrease in the frequency and severity of episodes. One patient had definite hereditary angioedema, and the other had probable hereditary angioedema but the family history was negative for the disease. The EACA therapy caused no major side effects.
Van Dellen
R G
RG
Division of Allergy and Outpatient Infectious Diseases and Internal Medicine, Mayo Clinic Rochester, MN 55905, USA.
D000328:Adult; D015119:Aminocaproic Acid / Q000627:therapeutic use*; D000799:Angioedema / Q000517:prevention & control; D000933:Antifibrinolytic Agents / Q000627:therapeutic use*; D003174:Complement C1 Inactivator Proteins / Q000172:deficiency*; D005260:Female; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000150:complications / Q000188:drug therapy*; D008297:Male
D000933:Antifibrinolytic Agents; D003174:Complement C1 Inactivator Proteins; D015119:Aminocaproic Acid